Ran across an interesting piece of news....
No money, no honey (or rather, no breast implants??? Honey, you don't need another implant or lets do it via instalments, the left one first and the right one 6 months later.....

)
hmmm how does it impact companies in Singapore?
Sluggish Economy Taking Its Toll On Cosmetic Surgery It’s Getting Ugly Out There
High-ticket items are hurt the worst, though many firms are feeling the pain
BY STEVE WATKINS FOR INVESTOR'S BUSINESS DAILY
Health care is a safe haven during a slow economy, right? That’s true for much of the sector, but parts of the health care field are just as susceptible to economic swings as cars, boats and furniture. In fact, you can call cosmetic treatment and laser eye surgery parts of consumer discretionary spending.
Some companies that provide these services say they’re seeing an impact from the downturn, and some don’t. But Anthony Vendetti, an analyst at Maxim Group, says the economy’s weakness is impacting the entire group. “There are companies that can buck this trend,†Vendetti said of the cyclical parts of health care. “But I don’t think any company is immune from the domestic downturn.â€
Tumbling Shares Unlike most parts of health care breast augmentation, wrinkle re moval and the like aren’t reim bursed by insurance or Medicare So companies in those areas rely on how much money consumers have to spare. The stocks show it. Shares of most providers of cosmetic surgery are trending down.
There’s no mystery why, analysts say. Plastic surgeons tell Piper Jaff ray analyst Thom Gunderson that their business is down 10% to 20 this year. That’s for procedures that might run $4,000 or more, such face-lifts, liposuction and breast aug mentation.
“Those are facing the realities the tough consumer economy that’ out there,†Gunderson said.
Botox and other methods used treat wrinkles don’t cost as much surgery. Some of those doctors’ businesses are up slightly, while others are down a bit, Gunderson says.
Sales of cosmetic lasers, which cost $100,000 to $200,000, are taking a big hit, says Jose Haresco, an analyst at Merriman Curhan Ford Group. They’ve gone from doubledigit growth to double-digit declines.
Most doctors need financing to buy such high-ticket items. As lending has tightened, loans haven’t been as available.
“That’s eviscerated a lot of the market opportunity,†Haresco said. Laser eye surgery volume was down 15% to 20% in the first quarter, Vendetti says. He expects it to fall more than that later this year.
Delaying Treatment While Vendetti figures the slump is temporary, he doesn’t see signs of the cycle changing soon. It’ll take housing prices to stop falling and oil prices to dip to get the cycle turned, he says. Until then, some companies’ markets aren’t getting hurt as badly as others.
Treatments such as Botox require repeat injections. Patients aren’t dropping the treatments, but they are putting them off. Instead of every three to six months, they might go in every four to 10 months. “You try to maintain it and not just stop cold turkey, or your face will sag as fast as the economy has,†Gunderson said.
That’s helped companies such as Botox-maker Allergan AGN weather the storm. Allergan has managed to churn out double-digit sales and profit growth through the economic slump. It’s expected to do the same over the next four quarters. Still, the stock is down nearly 20% since hitting an alltime high of 70.40 on Jan. 14.
Innovation also makes a difference. Cosmetic laser firm Cynosure CYNO , which in January launched a SmartLipo laser fat-removal product, has run off six straight quarters of 41%-or-better sales growth. Earnings have grown at least 80% the last five quarters, and the company’s stock is up more than 20% since hitting a 52-week low on March 10.
“Some companies have products that are in such high demand that they’re able to buck this trend,†Vendetti said. Not every company is bucking it, however. Palomar Medical Technologies PMTI , which makes cosmetic laser systems, hasn’t grown the bottom line since the fourth quarter of 2006. Its stock recently fell to 10.36, its lowest point since January 2004.
Last quarter Palomar lost 5 cents a share — its first shortfall in years — and posted a 27% year-over-year sales decline. The slow economy was partly to blame, Chief Executive Joseph Caruso said during a conference call.
“For the first time we have had a substantial decrease in sales from some of our most seasoned sales reps,†Caruso said. “Physicians appear to be postponing major buying decisions. This trend is fueled by a decrease in physician confidence in consumer spending.â€
Laser eye surgery stocks such as LCA-Vision LCAV also have taken a hit. Its procedures can run from $3,000 to $6,000, Vendetti says. That might be one reason sales grew only 1% last quarter and are expected to decline each of the next three quarters. Its stock currently trades at its lowest point in nearly five years.
Trading Down Mentor MNT , which controls about half of the U.S. breast implant market, has fared better. It continues to grow sales in double digits, though earnings have been down. Still, the high cost of its procedures — $5,000 to $10,000 each — poses a risk.
Some patients opt for less expensive silicone implants, Haresco says. “If people are willing to do it, they’re choosing the cheaper option,†he said. As for when the sector might bounce back: Gunderson figures it was among the last to feel the pinch, so it might be the first to come back when things get better.
“But it really is going to take a rebound in the economy,†he said.
Haresco reckons the stocks will lag, saying the economy will have to show strength for at least a quarter before people are comfortable spending again. That could be a while.
“We don’t see a strong recovery anytime soon,†he said.